Alaunos Therapeutics (TCRT) Total Non-Current Liabilities (2009 - 2023)
Alaunos Therapeutics' (TCRT) quarterly Total Non-Current Liabilities came in at $2.0 million in Q4 2023, down 92.58% YoY from $26.4 million in Q4 2022, and down 64.69% on a QoQ basis from $5.5 million in Q3 2023.
Alaunos Therapeutics (TCRT) Total Non-Current Liabilities (2009 - 2023) Analysis & Trends
Alaunos Therapeutics (TCRT) has 13 years of Total Non-Current Liabilities data on file, last reported at $2.0 million in Q4 2023.
- Quarterly Total Non-Current Liabilities fell 92.58% year-over-year to $2.0 million in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $2.0 million (down 92.58% YoY) and the FY2023 annual result came in at $2.0 million, down 92.58% from the prior year.
- Total Non-Current Liabilities declined to $2.0 million in Q4 2023, from $5.5 million in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $36.8 million in Q4 2021 to a low of $2.0 million in Q4 2023.
- A 3-year average of $20.6 million and a median of $22.7 million in 2022 frame the typical range for Total Non-Current Liabilities.
- Annual changes were most pronounced in 2022 — Total Non-Current Liabilities dropped 28.4% — and 2023, when it sank 92.58%.
- Tracing TCRT's Total Non-Current Liabilities over 3 years: stood at $36.8 million in 2021, then retreated by 28.4% to $26.4 million in 2022, then slumped by 92.58% to $2.0 million in 2023.
- The last three Total Non-Current Liabilities figures came in at $2.0 million (Q4 2023), $5.5 million (Q3 2023), and $6.3 million (Q2 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 724.15 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.17 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.32 Bn |
| 10 | Alaunos Therapeutics | 4.28 Mn | 4.16 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 1.96 Mn |
| Sep 30, 2023 | 5.54 Mn |
| Jun 30, 2023 | 6.28 Mn |
| Mar 31, 2023 | 19.10 Mn |
| Dec 31, 2022 | 26.35 Mn |
| Sep 30, 2022 | 35.20 Mn |
| Jun 30, 2022 | 33.72 Mn |
| Dec 31, 2021 | 36.81 Mn |
| Sep 30, 2018 | 60.19 Mn |
| Jun 30, 2018 | 58.83 Mn |
| Mar 31, 2018 | 59.10 Mn |
| Dec 31, 2017 | 56.00 Mn |
| Sep 30, 2017 | 54.94 Mn |
| Jun 30, 2017 | 54.37 Mn |
| Mar 31, 2017 | 57.48 Mn |
| Dec 31, 2016 | 57.46 Mn |
| Sep 30, 2016 | 59.03 Mn |
| Jun 30, 2016 | 179.31 Mn |
| Jun 30, 2015 | 13.58 Mn |
| Sep 30, 2014 | 12.61 Mn |